On May 4, 2013, the ministry of health of VietNam suspended Quinvaxem, the pentavalent combination used in that country, after it had caused 12 deaths and nine non-fatal serious adverse events (3). On investigating the reactions caused by the vaccine, the World Health Organization (WHO) reported that the nine non-fatal cases could correspond to known vaccine reactions, but the fatal cases were not related to the use of the vaccine.

The new National Vaccine Policy Draft 2011 by the Union Ministry of Health and Family Welfare comes out openly in favour of public-private partnerships and suggests flexible governing and funding mechanisms to support vaccine development in the PPP mode. This article argues that our vaccine policy must look into the health of the children in the country and it should not be overly concerned solely with the viability of the vaccine industry.

We are shocked and dismayed that The Lancet should have published the paper on the protective efficacy of monovalent oral type 1 poliovirus vaccine by Nicholas Grassly and colleagues (April 21, p 1356),1 having overlooked the serious ethical issues. (Correspondence) involved.